Exagen to Present at the William Blair 40th Annual Growth Stock Conference
Exagen Inc. (Nasdaq: XGN) announced that Ron Rocca, President and CEO, will present at the William Blair 40th Annual Growth Stock Conference on June 9 at 1:20 PM CDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) announced that Ron Rocca, President and CEO, will present at the William Blair 40th Annual Growth Stock Conference on June 9 at 1:20 PM CDT. This year's conference will be virtual, and a live webcast of the presentation will be accessible via the Exagen investor relations website. A replay will be available about one hour after the event concludes. Exagen focuses on transforming care for patients with autoimmune diseases through innovative testing products, including those based on proprietary CB-CAPs technology.
Details
News Market Reaction – XGN
The recorded move for XGN in the trading session of this news was -0.36%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that Ron Rocca, President and Chief Executive Officer of Exagen, will present at the William Blair 40th Annual Growth Stock Conference on Tuesday, June 9. The conference will be a virtual event this year. Mr. Rocca’s presentation will take place at 1:20 PM CDT.
A link to the live webcast of the presentation will be available online from the investor relations section of the Exagen website at https://investors.exagen.com/
A replay of the webcast will be accessible on the Exagen investor relations website beginning approximately one hour following the completion of the event.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on its proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis.
CONTACTS:
Investors
Westwicke Partners
Mike Cavanaugh
Mike.Cavanaugh@westwicke.com
646.677.1838
Company Contact
Exagen Inc.
Kamal Adawi, Chief Financial Officer
KAdawi@exagen.com
760.477.5514
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.